EMA Validates Daiichi Sankyo Applications for Two Combination Therapies

The EMA validated two marketing authorization applications from Daiichi Sankyo for oral, single-pill triple-combination therapies targeting adults with primary hypercholesterolemia or mixed dyslipidemia.